论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Lu S
Received 21 September 2018
Accepted for publication 14 December 2018
Published 22 February 2019 Volume 2019:12 Pages 1521—1538
DOI https://doi.org/10.2147/OTT.S188296
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Amy Norman
Peer reviewer comments 3
Editor who approved publication: Dr Arseniy Yuzhalin
Abstract: Lung
cancer is the leading cause of cancer death in China, and approximately one
third of these cancers are squamous cell carcinoma (SqCC) of the lung. Ethnic
diversity and country-specific environmental factors can account for
interindividual variations in response to and tolerability of anticancer
therapies. Although several targeted therapies have recently been approved for
patients with relapsed/refractory SqCC of the lung, only afatinib, an
irreversible ErbB family blocker, has data of Chinese patients. In the Phase
III LUX-Lung 8 trial, afatinib demonstrated a significant clinical benefit vs
the reversible first-generation EGFR tyrosine kinase inhibitor erlotinib in
both the overall population and the Chinese subset, with a manageable safety
profile. Emerging biomarker data from LUX-Lung 8 suggest that patients with
ErbB mutations, especially ErbB2, and those classified as “good” in the
VeriStrat® proteomic test, may benefit from afatinib
treatment in particular, regardless of ethnicity, and may get a long-term
response. In conclusion, afatinib is a valid second-line option for Chinese
patients with SqCC of the lung, and specific biomarkers may help guide in
treatment decision-making. Ongoing studies will provide further guidance on
afatinib’s place in the treatment algorithm, alongside the other novel targeted
therapies.
Keywords: squamous
cell carcinoma, NSCLC, Chinese, afatinib, EGFR, ErbB, biomarker